TerSera

7 articles about TerSera

• Goserelin Included in the National Comprehensive Cancer Network® (NCCN) Head and Neck Cancers Guidelines

  10/24/2023

  TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network® Head and Neck Cancers Panel included a category 2B recommendation for goserelin as useful, in certain circumstances, for recurrent, unresectable, or metastatic salivary gland tumors in Version 1.2024 of the Head and Neck Cancers Guidelines released on October 9, 2023.

• TerSera® to sponsor "NET Cancer Health Storylines" digital platform to support patients suffering from Carcinoid Syndrome Diarrhea

  12/7/2022

  TerSera Therapeutics announced a new sponsorship with the Carcinoid Cancer Foundation and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome.

• Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics

  9/8/2020

  Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.

• GTCR and TerSera Therapeutics Announce Acquisition of Xermelo

  8/3/2020

  GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.

• Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELOLexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer

  7/30/2020

  Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO®.

• AstraZeneca PLC Offloads Cancer Med Zoladex to TerSera in $320 Million Deal

  2/20/2017

• GTCR, Ed Fiorentino Form New Company TerSera

  2/5/2016